当地时间2月6日,礼来制药公布2024财年第四季度业绩及2025财年业绩指引。2024年,礼来制药全年营收450.4亿美元,同比增长32%,与此前公布的全年业绩预期相符;全年净利润(非GAAP)为105.9亿美元,同比增长102%。其中,替尔泊肽降糖和减重制剂合计贡献164.6亿美元的收入,占2024年收入的比重约36%。 以销售额而言,替尔泊肽在2024年的成绩不敌司美格鲁肽制剂的293.0...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.